Agomelatine and its therapeutic potential in the depressed patient |
| |
| Authors: | Sidney H Kennedy and Beata S Eisfeld |
| |
| Abstract: | Despite advances in understanding potential disease mechanisms and in developing novel therapeutic approaches to the treatment of major depressive disorder, the disease continues to carry an enormous personal, social, and economic burden. Agomelatine represents an important opportunity to advance the treatment of depression. It is a melatonergic (MT1 and MT2) agonist and serotonergic (5HT2C) antagonist. Evidence from animal models of depression, complements emerging clinical data. In a dose range of 25–50 mg daily, agomelatine is an effective antidepressant with a very favorable side-effect profile. In particular, sleep restorative action in the absence of sedation and minimal effect on sexual function suggests that agomelatine represents a worthwhile treatment alternative for patients with major depressive disorder. |
| |
| Keywords: | |
|
|
